Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
ClinicalTrials.gov record
Recruiting Phase 3 Interventional

Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).

ClinicalTrials.gov ID: NCT06641414

Public ClinicalTrials.gov record NCT06641414. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search
ClinicalTrials.gov public records Last synced Oct 23, 2026, 7:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Global Multicenter, Double-blind, Randomized, Registrational Phase 3 Study of Lisaftoclax (APG-2575) in Combination With Azacitidine (AZA) in Patients With Newly Diagnosed Higher Risk Myelodysplastic Syndrome (HR-MDS) (GLORA-4).

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

A global multicenter, randomized, double-blind, placebo-controlled, pivotal phase III study. To evaluate overall survival (OS) of lisaftoclax (APG-2575) combined with azacitidine (AZA) vs. placebo combined with azacitidine in newly diagnosed patients with HR-MDS.

Study identification

NCT ID
NCT06641414
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
Ascentage Pharma Group Inc.
Industry
Enrollment
490 participants

Conditions and interventions

Interventions

Drug · Other

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 22, 2025 (Actual)
Primary completion
Jun 2029 (Estimated)
Completion
Dec 2029 (Estimated)
Last update posted
Oct 13, 2026

2025 – 2029

United States locations

U.S. sites
40
U.S. states
24
U.S. cities
39
Facility City State ZIP Site status
Ascentage Investigative Site Birmingham Alabama 35294 Not yet recruiting
Ascentage Investigative Site Phoenix Arizona 85054 Recruiting
Ascentage Investigative Site Los Angeles California 90095 Recruiting
Ascentage Investigative Site Sacramento California 95817 Recruiting
Ascentage Investigative Site San Diego California 92093 Recruiting
Ascentage Investigative Site Aurora Colorado 80045 Recruiting
Ascentage Investigative Site Jacksonville Florida 32224 Recruiting
Ascentage Investigative Site Chicago Illinois 60611 Recruiting
Ascentage Investigative Site Indianapolis Indiana 46237 Recruiting
Ascentage Iowa City Iowa 52242 Not yet recruiting
Ascentage Investigative Site Louisville Kentucky 40202 Recruiting
Ascentage Investigative Site Baltimore Maryland 21201-1595 Recruiting
Ascentage Investigative Site Minneapolis Minnesota 55455 Recruiting
Ascentage Investigative Site Rochester Minnesota 55905 Recruiting
Ascentage Investigative Site St Louis Missouri 63110 Recruiting
Ascentage Investigative Site Lincoln Nebraska 68506 Recruiting
Ascentage Investigative Site Hackensack New Jersey 07601 Recruiting
Ascentage Investigative Site New York New York 10065 Recruiting
Ascentage Investigative Site Rochester New York 14642 Recruiting
Ascentage Investigative Site The Bronx New York 10467 Recruiting
Ascentage Investigative Site Charlotte North Carolina 28204 Recruiting
Ascentage Investigative Site Durham North Carolina 27705 Recruiting
Ascentage Investigative Site Winston-Salem North Carolina 27103 Recruiting
Ascentage Investigative Site Cleveland Ohio 44195 Recruiting
Ascentage Investigative Site Columbus Ohio 43210 Recruiting
Ascentage Investigative Site Eugene Oregon 97401 Recruiting
Ascentage Investigative Site Pittsburgh Pennsylvania 15232 Recruiting
Ascentage Investigative Site Providence Rhode Island 02903 Not yet recruiting
Ascentage Investigative Site Austin Texas 78705 Recruiting
Ascentage Investigative Site Houston Texas 77054 Recruiting
Ascentage Investigative Site Tyler Texas 75702 Recruiting
Ascentage Investigative Site Charlottesville Virginia 22908 Recruiting
Ascentage Investigative Site Manassas Virginia 20110 Recruiting
Ascentage Investigative Site Norfolk Virginia 23502 Recruiting
Ascentage Investigative Site Edmonds Washington 98026 Recruiting
Ascentage Investigative Site Issaquah Washington 98104 Recruiting
Ascentage Investigative Site Seattle Washington 98104 Recruiting
Ascentage Investigative Site Seattle Washington 98109 Recruiting
Ascentage Investigative Site Milwaukee Wisconsin 53266 Recruiting
Ascentage Investigative Site Waukesha Wisconsin 53188 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 114 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06641414, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 13, 2026 · Synced Oct 23, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT06641414 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →